Artemisinin Combination Therapy Market Size, Forecast [2030]

Segments - Artemisinin Combination Therapy Market by Type (Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, and Pyronaridine-Artesunate), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

Author : Raksha Sharma

Fact-checked by : Vineet Pandey

Editor : Vishal Golekar

Report Description

The global artemisinin combination therapy market size is estimated to expand at a high CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the increased demand for the therapy and recognition as first line treatment for malaria by the World Health Organization.

Artemisinin Combination Therapy Market Key takeaways

Treatment with effective anti-malarial medicines is critical for successful malaria control. Malaria-endemic countries have a National Malaria Therapy Policy that describes medicines for treating simple and severe malaria, as well as malaria in pregnancy and what to do if first-line treatment fails. Malaria is the most common parasite illness on the planet. It is estimated that it causes new episodes in over 214 million patients each year, killing around 438,000 people, the majority of whom are children under the age of five and pregnant women, not to mention incalculable economic damage in endemic nations. Malaria treatment has evolved significantly in recent years. In most cases of complicated malaria treatment, artesunate has proved to be preferable than quinine.

Artemisinin-based combination therapy (ACT) is suggested for the treatment of P. falciparum malaria. Artemisinin-based compounds that work quickly are coupled with a medication from a different class. Lumifantrine, mefloquine, amodiaquine, sulfadoxine/pyrimethamine, piperaquine, and chlorproguanil/dapsone are examples of companion medicines. Dihydroartemisinin, artesunate, and artemether are artemisinin derivatives. A co-formulated medication is one that has two distinct pharmaceuticals in one tablet; this is necessary to guarantee that both drugs are taken. When compared to any other anti-malarial, artemisinin treatment results in reduced hospital stays, faster parasite clearance, and, in the case of complex malaria, a reduced worldwide death rate. The bulk of these research were conducted in endemic regions. Treatment with artesunate also reduced the number of days spent in critical care units in patients with complex malaria in non-endemic countries (ICU). However, there are few research examining differences in non-endemic locations in individuals with uncomplicated P. falciparum malaria.

Market Trends, Drivers, Restraints, and Opportunities

Increasing prevalence of malaria worldwide is projected to fuel the market growth during the forecast period.
Artemisinin combination therapy is fast and effective for treatment this is expected to boost the market growth during the forecast period.
Increasing pipeline antimalarial drugs is anticipated to drive the market growth during the forecast period.
Growing R&D activities and improvement in healthcare infrastructure are factors driving the market growth in the coming years.
Favorable initiatives by public and private institutes for spreading the awareness regarding the diseases is projected to propel the market growth in the coming years.
Anti-malarial medication adverse effects, as well as the existence of counterfeit and inferior drugs are projected to hamper the market growth.
Increased R&D investment and technological advancements are anticipated to offer lucrative opportunities for the market players.

Scope of the Report

The report on the global artemisinin combination therapy market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes	Details
Report Title	Artemisinin Combination Therapy Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
Base Year	2020
Historic Data	2018–2019
Forecast Period	2021–2028
Segmentation	Type(Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, and Pyronaridine-Artesunate)
Regional Scope	Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
Report Coverage	Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
Key Players Covered in the Report	Novartis, Sanofi, Cipla, Ajanta Pharma, Ipca Laboratories, Guilin Pharmaceuticals, and KPC Pharmaceuticals

Market Segment Insights

Artemether+lumefantrine segment is expected to account for a key share
Based on type, the artemisinin combination therapy market is segmented into artemether+lumefantrine, artesunate+amodiaquine, dihydroartemisinin+piperaquine, artesunate+mefloquine, artesunate+sulfadoxine-pyrimethamine, and pyronaridine-artesunate. The artemether+lumefantrine segment is expected to account for a key share of the market during the forecast period owing to its efficacy, safety, and quality. It is marketed in over 80 countries and is the only ACT authorized by the US Food and Drug Administration. The WHO recommends that uncomplicated malaria, the most dangerous form of the disease, be treated with ACTs, as they are the most effective therapy available. Because parasites have developed resistance to alternative treatments such as Sulfadoxine-pyrimethamine, chloroquine, and artemisinin monotherapies, ACTs are preferred.

Artemisinin Combination Therapy Market By Types

Middle East & Africa is anticipated to dominate
On the basis of regions, the artemisinin combination therapy market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. Middle East & Africa is anticipated to dominate the market during the forecast period. The regional market growth can be attributed to presence of large population, artemisinin herbs, increased malaria control strategies, effective treatment, and control. Difficulty in logistics is projected to hamper the market growth. Several at-risk populations live in rural regions and WHO and other organizations are trying to eradicate severe poverty in Africa, thus the adoption rate of ACT is expected to rise further in the coming years.

On the other hand, Asia Pacific is expected to exhibit a rapid growth rate in the coming years owing to large production base of artemisinin herbs and rising demand in malaria endemic countries.

Artemisinin Combination Therapy Market By Regions

Segments

Segments Covered in the Report
The global artemisinin combination therapy market has been segmented on the basis of

Type

Artemether+Lumefantrine
Artesunate+Amodiaquine
Dihydroartemisinin+Piperaquine
Artesunate+Mefloquine
Artesunate+Sulfadoxine-Pyrimethamine
Pyronaridine-Artesunate

Regions

Asia Pacific
North America
Latin America
Europe
Middle East & Africa

Key Players

Novartis
Sanofi
Cipla
Ajanta Pharma
Ipca Laboratories
Guilin Pharmaceuticals
KPC Pharmaceuticals

Competitive Landscape

Key players competing in the artemisinin combination therapy market are Novartis, Sanofi, Cipla, Ajanta Pharma, Ipca Laboratories, Guilin Pharmaceuticals, and KPC Pharmaceuticals.

Some of the key business strategies employed by companies in the market includes mergers, acquisitions, partnerships, collaborations, capacity expansion, Research & Development of new products and product launches to increase their market shares.

Artemisinin Combination Therapy Market By Key Players

Table Of Content

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Artemisinin Combination Therapy Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Artemisinin Combination Therapy Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Artemisinin Combination Therapy Market - Supply Chain
  4.5. Global Artemisinin Combination Therapy Market Forecast
     4.5.1. Artemisinin Combination Therapy Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Artemisinin Combination Therapy Market Size (000â€™ Units) and Y-o-Y Growth
     4.5.3. Artemisinin Combination Therapy Market Absolute $ Opportunity
5. Global Artemisinin Combination Therapy Market Analysis and Forecast by Types
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Types
     5.2.2. Y-o-Y Growth Projections by Types
  5.3. Artemisinin Combination Therapy Market Size and Volume Forecast by Types
     5.3.1. Artemether+Lumefantrine
     5.3.2. Artesunate+Amodiaquine
     5.3.3. Dihydroartemisinin+Piperaquine
     5.3.4. Artesunate+Mefloquine
     5.3.5. Artesunate+Sulfadoxine-Pyrimethamine
     5.3.6. Pyronaridine-Artesunate
  5.4. Absolute $ Opportunity Assessment by Types
  5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global Artemisinin Combination Therapy Market Analysis and Forecast by Region
  6.1. Market Trends
  6.2. Introduction
     6.2.1. Basis Point Share (BPS) Analysis by Region
     6.2.2. Y-o-Y Growth Projections by Region
  6.3. Artemisinin Combination Therapy Market Size and Volume Forecast by Region
     6.3.1. North America
     6.3.2. Latin America
     6.3.3. Europe
     6.3.4. Asia Pacific
     6.3.5. Middle East and Africa (MEA)
  6.4. Absolute $ Opportunity Assessment by Region
  6.5. Market Attractiveness/Growth Potential Analysis by Region
  6.6. Global Artemisinin Combination Therapy Demand Share Forecast, 2019-2026
7. North America Artemisinin Combination Therapy Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
  7.2. North America Artemisinin Combination Therapy Market Size and Volume Forecast by Country
     7.2.1. U.S.
     7.2.2. Canada
  7.3. Absolute $ Opportunity Assessment by Country
  7.4. North America Artemisinin Combination Therapy Market Size and Volume Forecast by Types
     7.4.1. Artemether+Lumefantrine
     7.4.2. Artesunate+Amodiaquine
     7.4.3. Dihydroartemisinin+Piperaquine
     7.4.4. Artesunate+Mefloquine
     7.4.5. Artesunate+Sulfadoxine-Pyrimethamine
     7.4.6. Pyronaridine-Artesunate
  7.5. Basis Point Share (BPS) Analysis by Types
  7.6. Y-o-Y Growth Projections by Types
  7.7. Market Attractiveness/Growth Potential Analysis
     7.7.1. By Country
     7.7.2. By Product Type
     7.7.3. By Application
  7.8. North America Artemisinin Combination Therapy Demand Share Forecast, 2019-2026
8. Latin America Artemisinin Combination Therapy Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Latin America Average Pricing Analysis
  8.2. Latin America Artemisinin Combination Therapy Market Size and Volume Forecast by Country
      8.2.1. Brazil
      8.2.2. Mexico
      8.2.3. Rest of Latin America
   8.3. Absolute $ Opportunity Assessment by Country
  8.4. Latin America Artemisinin Combination Therapy Market Size and Volume Forecast by Types
     8.4.1. Artemether+Lumefantrine
     8.4.2. Artesunate+Amodiaquine
     8.4.3. Dihydroartemisinin+Piperaquine
     8.4.4. Artesunate+Mefloquine
     8.4.5. Artesunate+Sulfadoxine-Pyrimethamine
     8.4.6. Pyronaridine-Artesunate
  8.5. Basis Point Share (BPS) Analysis by Types
  8.6. Y-o-Y Growth Projections by Types
  8.7. Market Attractiveness/Growth Potential Analysis
     8.7.1. By Country
     8.7.2. By Product Type
     8.7.3. By Application
  8.8. Latin America Artemisinin Combination Therapy Demand Share Forecast, 2019-2026
9. Europe Artemisinin Combination Therapy Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Europe Average Pricing Analysis
  9.2. Europe Artemisinin Combination Therapy Market Size and Volume Forecast by Country
     9.2.1. Germany
     9.2.2. France
     9.2.3. Italy
     9.2.4. U.K.
     9.2.5. Spain
     9.2.6. Russia
     9.2.7. Rest of Europe
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Europe Artemisinin Combination Therapy Market Size and Volume Forecast by Types
     9.4.1. Artemether+Lumefantrine
     9.4.2. Artesunate+Amodiaquine
     9.4.3. Dihydroartemisinin+Piperaquine
     9.4.4. Artesunate+Mefloquine
     9.4.5. Artesunate+Sulfadoxine-Pyrimethamine
     9.4.6. Pyronaridine-Artesunate
  9.5. Basis Point Share (BPS) Analysis by Types
  9.6. Y-o-Y Growth Projections by Types
  9.7. Market Attractiveness/Growth Potential Analysis
     9.7.1. By Country
     9.7.2. By Product Type
     9.7.3. By Application
  9.8. Europe Artemisinin Combination Therapy Demand Share Forecast, 2019-2026
10. Asia Pacific Artemisinin Combination Therapy Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Asia Pacific Average Pricing Analysis
  10.2. Asia Pacific Artemisinin Combination Therapy Market Size and Volume Forecast by Country
     10.2.1. China
     10.2.2. Japan
     10.2.3. South Korea
     10.2.4. India
     10.2.5. Australia
     10.2.6. Rest of Asia Pacific (APAC)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Asia Pacific Artemisinin Combination Therapy Market Size and Volume Forecast by Types
     10.4.1. Artemether+Lumefantrine
     10.4.2. Artesunate+Amodiaquine
     10.4.3. Dihydroartemisinin+Piperaquine
     10.4.4. Artesunate+Mefloquine
     10.4.5. Artesunate+Sulfadoxine-Pyrimethamine
     10.4.6. Pyronaridine-Artesunate
  10.5. Basis Point Share (BPS) Analysis by Types
  10.6. Y-o-Y Growth Projections by Types
  10.7. Market Attractiveness/Growth Potential Analysis
     10.7.1. By Country
     10.7.2. By Product Type
     10.7.3. By Application
  10.8. Asia Pacific Artemisinin Combination Therapy Demand Share Forecast, 2019-2026
11. Middle East & Africa Artemisinin Combination Therapy Market Analysis and Forecast
  11.1. Introduction
     11.1.1. Basis Point Share (BPS) Analysis by Country
     11.1.2. Y-o-Y Growth Projections by Country
     11.1.3. Middle East & Africa Average Pricing Analysis
  11.2. Middle East & Africa Artemisinin Combination Therapy Market Size and Volume Forecast by Country
     11.2.1. Saudi Arabia
     11.2.2. South Africa
     11.2.3. UAE
     11.2.4. Rest of Middle East & Africa (MEA)
  11.3. Absolute $ Opportunity Assessment by Country
  11.4. Middle East & Africa Artemisinin Combination Therapy Market Size and Volume Forecast by Types
     11.4.1. Artemether+Lumefantrine
     11.4.2. Artesunate+Amodiaquine
     11.4.3. Dihydroartemisinin+Piperaquine
     11.4.4. Artesunate+Mefloquine
     11.4.5. Artesunate+Sulfadoxine-Pyrimethamine
     11.4.6. Pyronaridine-Artesunate
  11.5. Basis Point Share (BPS) Analysis by Types
  11.6. Y-o-Y Growth Projections by Types
  11.7. Market Attractiveness/Growth Potential Analysis
     11.7.1. By Country
     11.7.2. By Product Type
     11.7.3. By Application
  11.8. Middle East & Africa Artemisinin Combination Therapy Demand Share Forecast, 2019-2026
12. Competition Landscape
  12.1. Global Artemisinin Combination Therapy Market: Market Share Analysis
  12.2. Artemisinin Combination Therapy Distributors and Customers
  12.3. Artemisinin Combination Therapy Market: Competitive Dashboard
  12.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     12.4.1. Novartis
     12.4.2. Sanofi
     12.4.3. Cipla
     12.4.4. Ajanta Pharma
     12.4.5. Ipca Laboratories
     12.4.6. Guilin Pharmaceuticals
     12.4.7. KPC Pharmaceuticals